Boston Scientific (NYSE:BSX) said yesterday that it’s planning a three-year restructuring program that’s slated to cost at least $200 million.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,